<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380831</url>
  </required_header>
  <id_info>
    <org_study_id>20006</org_study_id>
    <secondary_id>NCI-2020-02744</secondary_id>
    <secondary_id>20006</secondary_id>
    <nct_id>NCT04380831</nct_id>
  </id_info>
  <brief_title>TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis</brief_title>
  <official_title>Pilot Study of Total Body Irradiation Using Intensity Modulated Radiation Therapy (IMRT) and Cyclophosphamide Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation in Patients With Severe Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies the side effects and feasibility of total body irradiation
      using intensity modulation radiation therapy (IMRT) when given in combination with
      cyclophosphamide prior to stem cell transplant to treat severe systemic sclerosis. IMRT
      delivers total body radiation therapy more precisely and may reduce radiation exposure to
      sensitive normal organs. Giving chemotherapy, such as cyclophosphamide, and total body
      irradiation before a donor stem cell transplant helps kill cancer cells in the body and helps
      make room in the bone marrow for new blood-forming cells (stem cells) to grow. Giving IMRT
      and cyclophosphamide prior to stem cell transplant may work better in treating severe
      systemic sclerosis and reduce radiation doses to lung and kidneys compared to
      cyclophosphamide alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the feasibility of using IMRT to deliver total body irradiation (TBI) to 800 cGy
      while keeping mean lung and kidney doses to 200 cGy.

      II. To assess the safety/feasibility of total body irradiation using IMRT (IMRT TBI) in
      systemic sclerosis patients undergoing autologous hematopoietic stem cell transplantation.

      SECONDARY OBJECTIVES:

      I. To evaluate dose homogeneity and dose sparing to lung and kidneys. II. To evaluate
      transplant-related mortality at 30 days and 100 days post IMRT TBI.

      OUTLINE:

      Patients undergo TBI using IMRT twice daily (BID) on days -5 and -4 in the absence of disease
      progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2
      and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up on days 30 and 100.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 22, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean lung dose</measure>
    <time_frame>Up to day 100</time_frame>
    <description>The study will be deemed feasible if &gt;= 80% of patients complete the intensity modulation radiation therapy (IMRT) to the total dose of 800 cGy, mean lung and kidney doses are limited to 200 cGy or less.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean kidney dose</measure>
    <time_frame>Up to day 100</time_frame>
    <description>The study will be deemed feasible if &gt;= 80% of patients complete the IMRT to the total dose of 800 cGy, mean lung and kidney doses are limited to 200 cGy or less.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose homogeneity for lungs, kidneys, and total body</measure>
    <time_frame>Up to day 100</time_frame>
    <description>&quot;Dose homogeneity for lung, kidney and total body will use the DVH (dose volume histograms) generated by the treatment plan for each of these regions. The goal is to keep the lung and kidney dose homogeneity to with +/- 15% of the mean dose to that organ. The goal is to keep total body dose homogeneity to within +/- 15% of the prescribed total body dose of 8 Gy.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Day 30 and day 100</time_frame>
    <description>Measured by comparing the transplant-related mortality rates on day 30 compared to day 100.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>Treatment (TBI using IMRT, cyclophosphamide, HSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo HSCT</description>
    <arm_group_label>Treatment (TBI using IMRT, cyclophosphamide, HSCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Undergo HSCT</description>
    <arm_group_label>Treatment (TBI using IMRT, cyclophosphamide, HSCT)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo TBI using IMRT</description>
    <arm_group_label>Treatment (TBI using IMRT, cyclophosphamide, HSCT)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
    <other_name>Radiation, Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI using IMRT</description>
    <arm_group_label>Treatment (TBI using IMRT, cyclophosphamide, HSCT)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky performance status (KPS) &gt;= 70

          -  Systemic sclerosis patients evaluated within 30 days of start of conditioning regimen
             who would be candidates for TBI-cyclophosphamide (Cy) per City of Hope (COH)
             guidelines and standard operating procedures (SOP) for autologous hematopoietic cell
             transplant

          -  Patients must be suitable for TBI conditioning regimens as part of transplant per
             radiation the referring hematologist

          -  Patients must have adequate organ function for HCT as determined by the hematologist

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control or abstinence) prior to study entry and
             for six months following duration of study participation

          -  All subjects must have the ability to understand the treatment and the willingness to
             sign a written informed consent

        Exclusion Criteria:

          -  Patients should not have any uncontrolled illness including ongoing or active
             infection

          -  Prior history of radiation therapy must be presented to study principal investigator
             (PI) for eligibility determination

          -  Pregnant women are excluded from this study because total body irradiation is an agent
             with the potential for teratogenic or abortifacient effects

          -  Subjects, who in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Y Wong</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Y. Wong</last_name>
      <phone>626-218-2247</phone>
      <email>jwong@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Y. Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

